Immune checkpoint inhibition also holds promise as a treatment strategy, because HER2-positive breast cancers frequently have high levels of tumor-infiltrating lymphocytes and programmed cell death protein ligand 1 (PD-L1) expression, similar to other disease sites known to be responsive to immune checkpoint inhibition. Here, ERBB2 is linked to breast carcinoma.